OWC-1808

**OWC-1808** is an investigational, highly concentrated cannabinoid delivery formulation developed by OWC Pharmaceutical Research through its Israeli subsidiary One World Cannabis. It is designed to deliver high doses of cannabidiol and tetrahydrocannabinol with enhanced bioavailability and was initially developed for multiple myeloma. In 2018, OWC reported that the formulation was administered in an in vivo animal model and was safe and tolerable; no human clinical development details, dosage form, route, or molecularly defined target mechanism were disclosed in the identified public materials. ([prnewswire.com](https://www.prnewswire.com/news-releases/owc-pharmaceutical-research-corp-to-meet-with-investors-researchers-and-business-partners-at-2018-mjbizcon-revealing-the-testing-of-novel-formulation-for-multiple-myeloma-therapy-300744688.html))